LIR Life Sciences Corp.
SKNY
CNSX
| 10/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Net Income | -38.43% | 7.53% | |||
| Total Depreciation and Amortization | 25.00% | -- | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | -200.00% | -- | |||
| Change in Net Operating Assets | 106.67% | -315.79% | |||
| Cash from Operations | 88.60% | -322.50% | |||
| Capital Expenditure | -- | -- | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | 100.00% | -- | |||
| Cash from Investing | 100.00% | -- | |||
| Total Debt Issued | -85.71% | -100.00% | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | 2,931.37% | -100.00% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 993.03% | -328.38% | |||